Substituted macrocyclic indole derivatives

US11891404B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• The Broad Institute, Inc. · US

Inventors

• Kai Thede · Leverkusen, DE
• Anne Mengel · Berlin, DE
• Clara Christ · Leverkusen, DE
• Joachim Kuhnke · Leverkusen, DE
• Sarah Anna Liesa Johannes · Düsseldorf, DE
• Philipp Buchgraber · Leverkusen, DE
• Ulrich Klar · Berlin, DE
• Ulrike Rauh · Leverkusen, DE
• Stefan Kaulfuss · Berlin, DE
• Amaury Ernesto Fernandez-Montalvan · Leverkusen, DE
• Nicolas Werbeck · Berlin, DE
• Ursula Moenning · Mölln, DE
• Katrin Nowak-Reppel · Leverkusen, DE
• Sven Wittrock · Berlin, DE
• David McKinney · Cambridge, US
• Michael H. Serrano-Wu · Cambridge, US
• Chris Lemke · Cambridge, US
• Mark Fitzgerald · Cambridge, US
• Christopher G. Nasveschuk · Stoneham, US
• Kiel Lazarski · Cambridge, US
• Steven James Ferrara · Cambridge, US
• Laura Furst · Cambridge, US
• Guo Ping Wei · Richmond, US
• Patrick R. McCarren · Cambridge, US
• Rebecca Ann Harvey · Thornley with Wheatley, GB

Key dates

• Filing date: Sep 8, 2022
• Grant date: Feb 6, 2024
• Expiry date: Sep 8, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/22
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to substituted macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.